国药股份(600511) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 12,713,002,292.38, representing a 4.87% increase compared to CNY 12,122,142,562.33 in the same period last year[4]. - The net profit attributable to shareholders was CNY 459,015,386.52, showing a slight decrease of 0.10% from CNY 459,454,518.02 year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 446,230,701.31, down 2.57% from CNY 457,982,149.39 in the previous year[4]. - The basic earnings per share for the period was CNY 0.6084, a decrease of 0.08% from CNY 0.6089 in the same period last year[4]. - The diluted earnings per share also stood at CNY 0.6084, reflecting the same decrease of 0.08% year-on-year[4]. - Operating profit for Q1 2025 was ¥600.66 million, slightly down from ¥613.80 million in Q1 2024[17]. - The company reported an investment income of ¥116.03 million in Q1 2025, up from ¥104.98 million in Q1 2024[16]. - The company experienced a decrease in comprehensive income, totaling ¥484.98 million in Q1 2025, compared to ¥489.27 million in Q1 2024[18]. - The net profit for the first quarter of 2025 was CNY 337.04 million, up by 6.8% from CNY 315.67 million in the same period last year[26]. Cash Flow - The net cash flow from operating activities was negative at CNY -1,893,175,718.90, compared to CNY -1,719,799,376.67 in the same period last year[4]. - Cash flow from operating activities showed a net outflow of ¥1.89 billion in Q1 2025, compared to a net outflow of ¥1.72 billion in Q1 2024[20]. - The net cash flow from operating activities for Q1 2025 was -182,256,312.16, an improvement from -301,387,089.18 in Q1 2024, indicating a reduction in cash outflow[29]. - Total cash inflow from operating activities in Q1 2025 was 5,789,069,778.39, compared to 5,539,406,936.00 in Q1 2024, reflecting a year-over-year increase of approximately 4.5%[29]. - Cash outflow from operating activities in Q1 2025 was 5,971,326,090.55, up from 5,840,794,025.18 in Q1 2024, representing an increase of about 2.2%[29]. - The cash inflow from operating activities was primarily driven by sales revenue of 5,778,772,698.76 in Q1 2025, compared to 5,414,211,225.58 in Q1 2024, marking an increase of approximately 6.7%[29]. - The company reported a cash outflow of 234,445,715.29 for taxes paid in Q1 2025, compared to 194,489,069.09 in Q1 2024, which is an increase of about 20.5%[29]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 35,096,471,073.69, a 0.48% increase from CNY 34,928,279,243.62 at the end of the previous year[5]. - The total assets of the company as of March 31, 2025, amounted to CNY 35,096,471,073.69, an increase from CNY 34,928,279,243.62 at the end of 2024[12]. - The company's current assets totaled CNY 30,442,472,468.14, slightly up from CNY 30,356,823,125.08 in the previous period[12]. - The total liabilities decreased to CNY 15,636,451,007.66 from CNY 15,953,235,952.60[13]. - The company's total current liabilities decreased to CNY 10.66 billion as of March 31, 2025, down from CNY 12.22 billion at the end of 2024, a reduction of approximately 12.8%[23]. - The company's cash and cash equivalents were reported at CNY 8,847,209,696.57, down from CNY 10,885,676,736.04[11]. - Cash and cash equivalents at the end of Q1 2025 were ¥6.27 billion, down from ¥9.19 billion at the end of Q1 2024[20]. - The cash and cash equivalents decreased to CNY 8.22 billion from CNY 10.30 billion, a decline of about 20.2%[22]. - The ending cash and cash equivalents balance for Q1 2025 was 5,670,552,754.10, down from 8,279,843,440.17 in Q1 2024, reflecting a decrease of about 31%[31]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 48,500[9]. - The equity attributable to shareholders increased by 2.68% to CNY 17,587,021,750.39 from CNY 17,128,090,785.52 at the end of the previous year[5]. - The company's equity attributable to shareholders increased to CNY 17,587,021,750.39 from CNY 17,128,090,785.52[14]. - The total equity increased to CNY 14.16 billion as of March 31, 2025, compared to CNY 13.83 billion at the end of 2024, reflecting a growth of approximately 2.4%[24]. Inventory and Receivables - Accounts receivable rose to CNY 14,262,746,580.18 from CNY 12,330,407,168.68, indicating a growth of approximately 15.7%[11]. - Inventory levels increased to CNY 5,042,936,676.44 from CNY 4,955,697,408.61, reflecting a growth of about 1.8%[12]. - The company's inventory remained stable at CNY 2.51 billion, showing a slight increase of 0.03% compared to CNY 2.51 billion at the end of 2024[22]. - The total non-current assets amounted to CNY 4,653,998,605.55, up from CNY 4,571,456,118.54[12]. Financial Expenses and Income - The company's financial expenses improved, with a net financial income of CNY 3.39 million in Q1 2025, compared to a loss of CNY 20.26 million in Q1 2024[25]. - The company reported an increase in investment income to CNY 113.86 million in Q1 2025, up from CNY 106.55 million in the same quarter of the previous year[25].